Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $276,908.28 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 22,082 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $12.54, for a total transaction of $276,908.28. Following the sale, the insider directly owned 202,380 shares of the company’s stock, valued at approximately $2,537,845.20. This represents a 9.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Thursday, May 7th, James Woodruff Lillie sold 721 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.28, for a total transaction of $20,389.88.
• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.

Maplight Therapeutics Stock Performance

Shares of NASDAQ:MPLT opened at $13.28 on Friday. The stock’s 50-day moving average is $29.35 and its 200-day moving average is $24.77. The company has a market cap of $565.99 million and a P/E ratio of -0.32. Maplight Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, equities analysts predict that Maplight Therapeutics, Inc. will post -5.22 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MPLT. Strs Ohio bought a new position in Maplight Therapeutics during the fourth quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $70,000. New York State Common Retirement Fund bought a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $93,000. MetLife Investment Management LLC bought a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics in the 4th quarter valued at $205,000.

Wall Street Analysts Forecast Growth

MPLT has been the subject of several research reports. Lifesci Capital raised Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Morgan Stanley reiterated an “equal weight” rating and set a $21.00 target price (down from $34.00) on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maplight Therapeutics in a report on Monday, July 13th. Wolfe Research restated an “outperform” rating and issued a $30.00 price target on shares of Maplight Therapeutics in a research report on Monday, July 27th. Finally, HC Wainwright cut their price objective on shares of Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $34.42.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.